12:00 AM
 | 
Jul 17, 2006
 |  BioCentury  |  Emerging Company Profile

Acceleron: Value in the wallflower

Acceleron Pharma Inc. is developing protein therapeutics that target the transforming growth factor beta superfamily to treat diseases ranging from musculoskeletal and metabolic disorders to cancer. Last month, Acceleron began Phase I testing of its lead candidate, ACE-011, a first-in-class activin receptor IIa antagonist to treat bone loss disorders.

President and CEO Glenn Batchelder said TGF beta bone growth factors represent "an under-appreciated space in biology that had not been exploited for its therapeutic potential."

Indeed, the first thing the company did after setting up shop was to accumulate as much of the available IP covering TGF beta as possible through licensing agreements with an assortment of academic institutions including the...

Read the full 543 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >